Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1301 to 1350 of 3761 results for treatment

  1. Eplontersen for treating hereditary transthyretin-related amyloidosis (TA1020)

    Evidence-based recommendations on eplontersen (Wainzua) for treating hereditary transthyretin-related amyloidosis in adults.

  2. Integrated health and social care for people experiencing homelessness (NG214)

    This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.

  3. Irreversible electroporation for treating liver metastases (HTG304)

    Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.

  4. Bronchiolitis in children (QS122)

    This quality standard covers assessing, diagnosing and managing bronchiolitis in children. It describes high-quality care in priority areas for improvement.

  5. What is the clinical effectiveness of negative pressure wound therapy in the treatment of diabetic foot ulcers?

    is the clinical effectiveness of negative pressure wound therapy in the treatment of diabetic foot ulcers? Any explanatory notes(if...

  6. Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) (TA978)

    NICE is unable to make a recommendation on zanubrutinib (Brukinsa) with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma in adults after 2 or more treatments. This is because BeiGene has requested a delay to the evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA978

  7. Somatrogon for treating growth disturbance in children and young people aged 3 years and over (TA863)

    Evidence-based recommendations on somatrogon (Ngenla) for treating growth disturbance in children and young people aged 3 years and over.

  8. Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen (TA1087)

    Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in adults.

  9. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

  10. What is the clinical effectiveness of clozapine for children and young people with schizophrenia with symptoms unresponsive to antipsychotic medication and psychological treatment combined?

    with symptoms unresponsive to antipsychotic medication and psychological treatment combined? Any explanatory notes(if applicable) The...

  11. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

    Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.

  12. Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (TA864)

    Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.

  13. What is the effectiveness of chemical peels for the treatment of acne vulgaris or persistent acne vulgaris-related scarring?

    Question What is the effectiveness of chemical peels for the treatment of acne vulgaris or persistent acne vulgaris-related scarring?...

  14. Digital technologies to support self-management of asthma: early value assessment

    In development Reference number: GID-HTE10063 Expected publication date:  30 April 2026

  15. Hyperhidrosis: oral glycopyrronium bromide (ESUOM16)

    Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

  16. Infantile haemangioma: topical timolol (ESUOM47)

    Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making

  17. Decreasing pharmacological treatment:- In adults, young people and children with well-controlled asthma, what are the objective measurements and prognostic factors that indicate that a decrease in regular maintenance treatment is appropriate?

    Recommendation ID NG80/9 Question Decreasing pharmacological treatment:- In adults, young people and children with well-controlled...

  18. Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)

    Summary of the evidence on delafloxacin for community-acquired pneumonia in adults

  19. Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

    Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.

  20. Transition between inpatient mental health settings and community or care home settings (QS159)

    This quality standard covers transitions for children, young people and adults between mental health hospitals and their own homes, care homes or other community settings. It includes the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It describes high-quality care in priority areas for improvement.

  21. Antenatal care (NG201)

    This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support.

  22. What is the most effective first-line treatment option for any severity of acne vulgaris for people with polycystic ovary syndrome?

    NG198/2 Question What is the most effective first-line treatment option for any severity of acne vulgaris for people with polycystic...

  23. Physical treatments for acne vulgaris and acne vulgaris-related scarring:  What is the effectiveness of chemical peels for the treatment of acne vulgaris or persistent acne vulgaris-related scarring?

    Physical treatments for acne vulgaris and acne vulgaris-related scarring: What is the effectiveness of chemical peels for the...

  24. Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)

    Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making

  25. Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) (TA859)

    After discussion with Paion AG, NICE is unable to make a recommendation on angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock. The company did not make an evidence submission because of uncertainty about the number of people who would be eligible for treatment. We will review this decision if the company decides to make a submission.

    Sections for TA859

  26. HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)

    This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.

  27. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

  28. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

    Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia in adults.

  29. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  30. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

  31. Community pharmacies: promoting health and wellbeing (NG102)

    This guideline covers how community pharmacies can help maintain and improve people’s physical and mental health and wellbeing, including people with a long-term condition. It aims to encourage more people to use community pharmacies by integrating them within existing health and care pathways and ensuring they offer standard services and a consistent approach. It requires a collaborative approach from individual pharmacies and their representatives, local authorities and other commissioners.

  32. Digital technologies to support monitoring of vision change at home for people with age-related macular degeneration: early use assessment

    In development Reference number: GID-HTE10073 Expected publication date:  15 September 2026

  33. Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care (NG26)

    This guideline covers the identification, assessment and treatment of attachment difficulties in children and young people up to age 18 who are adopted from care, in special guardianship, looked after by local authorities in foster homes (including kinship foster care), residential settings and other accommodation, or on the edge of care. It aims to address the many emotional and psychological needs of children and young people in these situations, including those resulting from maltreatment.

  34. Hypersexuality: fluoxetine (ESUOM46)

    Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making

  35. Heart valve disease presenting in adults: investigation and management (NG208)

    This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.

  36. Liver disease (QS152)

    This quality standard covers identifying, assessing and managing chronic liver disease in children, young people and adults, and cirrhosis in young people and adults. It describes high-quality care in priority areas for improvement.

  37. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)

    Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.

  38. Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)

    Summary of the evidence on antimicrobial prescribing: delafloxacin

  39. What is the clinical and cost effectiveness of treatment (antithyroid drugs or radioactive iodine) for improving long-term health outcomes for people with subclinical hyperthyroidism?

    NG145/2 Question What is the clinical and cost effectiveness of treatment (antithyroid drugs or radioactive iodine) for improving...

  40. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

  41. Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

    Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

  42. Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

    Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

  43. Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

    Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

  44. Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

  45. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 12 February 2026.

  46. What is the effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes?

    Question What is the effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes? Any explanatory...

  47. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)

    Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.

  48. Antibiotics for suspected early-onset infection: What is the optimal antibiotic dosage regimen for the treatment of early-onset neonatal infection?

    early-onset infection: What is the optimal antibiotic dosage regimen for the treatment of early-onset neonatal infection? Any...